Q4 2025 IPCA Laboratories Ltd Earnings Call Transcript

May 30, 2025 / 10:00AM GMT

Release Date Price: ₹1424.8 (-3.07%)

Transcript

Key Points

Positve

Ipca Laboratories Ltd (BOM:524494) reported a domestic business growth of 11% for Q4 and 12% for the full year, outperforming the overall market growth.
The company improved its market share in the chronic segment, with a growth rate of 17.9% compared to the market's 9.8%.
Consolidated EBITDA margins improved significantly, reaching 18.94% for FY25, up from 16.72% in FY24.
The company's export formulation business, particularly the branded formulation segment, showed a growth of 10% for FY25.
Unichem, a subsidiary of Ipca Laboratories Ltd, delivered a consolidated growth of 18% and improved its EBITDA margin from 4.87% to 12.55%.

Negative

The generic business in South Africa saw a significant decline of 74% due to the loss of certain tenders.
The US market contribution was minimal, with only INR 22-23 crores in sales, indicating a slow ramp-up in this region.
The CIS market growth was muted at 2% due to currency fluctuations, impacting the overall value growth.
The company's API business showed minimal growth, with only a 1% increase for the full financial year.
There was a decline in the Middle East and Africa markets by 21%, affecting the overall branded generic business.

Operator

Ladies and gentlemen, good day, and welcome to IPCA Labs Q4 FY25 Earnings Conference Call hosted by DAM Capital Advisors. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Nitin Agarwal from DAM Capital Advisors. Thank you, and over to you, sir.

Nitin Agarwal

DAM Capital Advisors Limited - Analyst

Thank you, Yousef. Good afternoon, everyone, and a very warm welcome to IPCA Laboratories Q4 F '25 Earnings Call, hosted by DAM Capital Advisors Limited. On the call today representing IPCA management, we've got Mr. A.K. Jain, managing Director; and Mr. Harish Kamath, Corporate Counsel and Company Secretary.

I will hand over the call to Mr. Jain to make the opening comments, and we will open the floor for questions. Mr. Jain, please go ahead, sir.

Ajit Jain

IPCA Laboratories Ltd - Chief Financial Officer, Managing Director, Executive Director

Thanks, Nitin, and DAM Capital Advisers for organizing this call, and welcome to all participants.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.